Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT

User menu

Search

  • Advanced search
eNeuro
eNeuro

Advanced Search

 

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT
PreviousNext
Research ArticleResearch Article: New Research, Disorders of the Nervous System

Characterizing the Diversity of Layer 2/3 Human Neocortical Neurons in Pediatric Epilepsy

J. Keenan Kushner, Paige B. Hoffman, Christine R. Brzezinski, Matthew N. Svalina, Brent R. O’Neill, Todd C. Hankinson, Charles C. Wilkinson, Michael H. Handler, Serapio M. Baca, Molly M. Huntsman and Allyson L. Alexander
eNeuro 17 April 2025, 12 (5) ENEURO.0247-24.2025; https://doi.org/10.1523/ENEURO.0247-24.2025
J. Keenan Kushner
1Neuroscience Graduate Program, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
2Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
3Department of Neurosurgery, School of Medicine, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for J. Keenan Kushner
Paige B. Hoffman
1Neuroscience Graduate Program, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
3Department of Neurosurgery, School of Medicine, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine R. Brzezinski
3Department of Neurosurgery, School of Medicine, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew N. Svalina
1Neuroscience Graduate Program, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
2Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
4Medical Scientist Training Program, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
5Department of Cell and Developmental Biology, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brent R. O’Neill
1Neuroscience Graduate Program, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
3Department of Neurosurgery, School of Medicine, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Todd C. Hankinson
1Neuroscience Graduate Program, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
3Department of Neurosurgery, School of Medicine, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles C. Wilkinson
1Neuroscience Graduate Program, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
3Department of Neurosurgery, School of Medicine, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael H. Handler
1Neuroscience Graduate Program, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
3Department of Neurosurgery, School of Medicine, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Serapio M. Baca
2Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
6Department of Pharmacology, University of Virginia, Charlottesville, Virginia 22903
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Molly M. Huntsman
1Neuroscience Graduate Program, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
2Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
7Department of Pediatrics, School of Medicine, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allyson L. Alexander
1Neuroscience Graduate Program, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
3Department of Neurosurgery, School of Medicine, University of Colorado | Anschutz Medical Campus, Aurora, Colorado 80045
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Extended Data
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Putative L2/3 PNs from human epileptic foci have diverse morphology and spiking properties. Ai–Ei, Depolarizing current steps at rheobase (pA; dark trace) and rheobase + 100 pA (2× rheobase, light trace) elicit action potentials (APs) of various shapes and frequencies. Each group was determined based on firing property and AHP shape. Aii–Eii, Representative trace of each AP from neuron subtype (scale bars: 10 mV, 10 ms). Aiii–Eiii, Corresponding 3D reconstruction of neuron morphology (x-axis scale bar: 200 µm). Each neuron's location in the representative cortical layers was determined by the respective distance of their soma from pial surface (dendrites: subtype color scheme, axon branches: blue).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Putative L2/3 PN subtypes show subtle differences in AP kinetics and firing properties. A, Neuron subtype percentage (%) of the entire population of recorded neurons (ACC, accommodating neurons; RS, regular spiking neurons; Not, notch neurons; ST, stuttering neurons; ES, early spiking neurons). B, Representative traces of L2/3 PN subtype AP (scale bars: 10 mV, 10 ms). C, Overlay of average AP of each neuron subtype. D, Overlay of average phase plot (dV/dT vs voltage) indicating differences in subtype AP kinetics. E, Notch neurons showed the shortest AP half-width with a significant difference compared with accommodating neurons. F, Stutter neurons showed a significant reduction in AP spike amplitude. G, Notch neurons have the shortest AHP latency with a significantly shorter AHP latency compared with RS and ACC neurons. H, FR accommodation ratio of each neuron subtype taken at 2× rheobase indicated ES neurons had a significantly lower chance of accommodating compared with stutter neurons. I, Initial instantaneous frequency ± SEM versus injected current (pA). J, Initial instantaneous frequency was taken at the rheobase + 100 pA current step and indicated significant differences between subtype initial instantaneous firing frequency. K, Final instantaneous frequency ± SEM versus injected current (pA). Scatterplots include mean values ± SD.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Epileptic L2/3 PNs with fAHP or mAHP do not differ in their firing rates or firing rate accommodation. A, Representative traces of L2/3 PN AP shapes showing neurons with a (Ai) fAHP followed by mAHP, (Aii) fAHP followed by ADP and mAHP, and (Aiii) mAHP only. B, Overlay of average AP of neuron split by AHP shape. C, Overlay of average phase plots (dV/dT vs voltage) of neuron split by AHP shape. D, There is no significant differences in the maximum depolarization slope of the AP (dV/dT) between subtypes. E, mAHP PNs have a significantly slower repolarization slope (dV/dT) when compared with fAHP PNs. F, AHP latency is shorter for fAHP and ADP PNs as expected compared with mAHP neurons. G, fAHP and ADP PNs show a more positive ΔAHP. H, mAHP PNs have more AP amplitude adaptation compared with ADP PNs. I, mAHP PNs have higher overall voltage sag (%) compared with fAHP PNs. We observe no differences in J, initial instantaneous frequency ± SEM versus injected current (pA); K, mean instantaneous frequency ± SEM versus injected current (pA); L, final instantaneous frequency ± SEM versus injected current (pA); or M, FR accommodation ratio ± SEM versus injected current (pA). N, Percentage (%) of AHP PN based on cell type characterized in Figure 2. f, fAHP; ADP, fAHP-ADP; m mAHP. Scatterplots include mean values ± SD.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Epileptic L2/3 PNs show minor differences between etiology, but crucial differences compared with control neurons. A, Representative traces from current (pA) ramp protocol (1,000 pA, 1 s) of L2/3 PNs from control (blue), MCD epileptic (purple), and other epileptic (OE) tissue (green). B, Representative traces from L2/3 PNs from control and epileptic subtype showing the corresponding −250 pA hyperpolarizing step (darker negative trace), rheobase step (darker positive trace), and 2× rheobase (lighter positive trace) depolarizing current step (600 ms steps). C, Percentage (%) of PNs with certain AHP cell type based on control and epilepsy subtype. D, Overlay of average AP of control and epileptic subtype L2/3 PNs. E, Overlay of average phase plots (dV/dT vs voltage) of control and epileptic subtype L2/3 PNs. F, MCD L2/3 PNs have a depolarized AP threshold compared with control. G, OE L2/3 PNs have significantly longer AP half-widths compared with MCD with trends toward longer half-widths in both epileptic subtype PNs compared with control PNs. H, Depolarization slopes (dV/dT) were significantly slower in both epileptic subtypes compared with control. I, AHP magnitude (mV) is significantly larger in both epileptic subtypes compared with control. J, Epileptic L2/3 PNs show a wide variability in input resistance. MCD L2/3 PNs on average have significantly higher input resistances compared with control and OE L2/3 PNs. K, Voltage sag is significantly smaller in both epileptic subtypes compared with control. L, Left, Mean FR ± SEM versus injected current (pA). L, Right, We observed lower max firing rate for both epileptic subtypes compared with control. M, Left, FR accommodation ratio ± SEM versus injected current (pA). M, Right, FR accommodation ratios indicate a lack of FR accommodation by OE L2/3 PNs compared with MCD L2/3 PNs with no differences compared with control. Although, on average, control PNs accommodate their frequency the most compared with the epileptic subtype PNs. Scatterplots include mean values ± SD.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    4-AP increases L2/3 PN AP half-width and AHP latency and decreases AHP magnitude leading to sustained firing. A, Overlay of a representative AP before and after 4-AP wash on (scale bars: 10 mV, 10 ms). Bi, Overlay of average AP before and after 4-AP wash on. Bii, Overlay of phase plots. C, Input resistance (MΩ) decreased after 4-AP wash on. D, AP half-width increased after 4-AP wash on. E, AP threshold became hyperpolarized after 4-AP wash on. F, AHP magnitude was reduced after 4-AP wash on G, AHP latency got slower after 4-AP wash on. H, AP amplitude was not different after 4-AP wash on. I, Left, Mean FR ± SEM versus injected current (pA). I, Right, No significant difference was found for mean Max FR after 4-AP wash on. J, FR accommodation ratio ± SEM versus injected current (pA) before and after 4-AP wash on at 400, 500, 600, 750, 800, and 850 pA depolarizing current steps indicates a significant absence of accommodation after 4-AP wash on. Scatterplots include mean values ± SD.

Tables

  • Figures
  • Extended Data
    • View popup
    Table 1.

    Patient information

    Final pathological diagnosisExperimental groupRegion of tissue resectionPatient age at surgery (years)Patient sex

    Anaplastic

    Pleomorphic Xanthoastrocytoma

    ControlParietal lobe21M
    GerminomaControlParietal lobe11M
    EmbryomaControlTemporal lobe9M
    Atypical meningiomaControlParietal lobe8F
    GliomaControlTemporal lobe1M
    FCD 1BMCDTemporal tip9F
    FCD IAMCDLateral temporal lobe17F
    FCD ICMCDFrontal lobe, temporal tip7M
    FCD IIAMCDFrontal lobe2F
    Mild MCDMCDFrontal lobe3F
    Tuberous SclerosisMCDFrontal lobe10M
    FCD IIAMCDOccipital lobe19M
    FCD IIBMCDFrontal lobe2F
    FCD IIIDMCDLateral temporal lobe6M
    FCD IIIDMCDTemporal lobe, frontal lobe18M
    Tuberous SclerosisMCDTemporal lobe15M
    FCD IIAMCDFrontal lobe2F
    FCD IIBMCDFrontal lobe7F
    Chaslin's subpial gliosisOther epilepsyLateral temporal lobe18M
    Chaslin's subpial gliosisOther epilepsyLateral temporal lobe20M
    EncephalomalaciaOther epilepsyFrontal lobe18M
    Chaslin's subpial gliosisOther epilepsyLateral temporal lobe5F
    GangliogliomaOther epilepsyTemporal tip16F
    Chaslin's subpial gliosisOther epilepsyFrontal lobe5M
    Chaslin's subpial gliosisOther epilepsyLateral temporal lobe10M
    Gliosis and MeningioangiomatosisOther epilepsyParietal lobe16F
    GliosisOther epilepsyFrontal lobe6M
    GliosisOther epilepsyTemporal lobe5M
    Low-grade glial neoplasmOther epilepsyTemporal lobe1F
    DNETOther epilepsyTemporal lobe10F
    Low-grade glioma, WHO grade IOther epilepsyTemporal lobe8M
    Chaslin's subpial gliosisOther epilepsyTemporal lobe, frontal lobe16M
    DNETOther epilepsyFrontal lobe6F
    • Demographic information, diagnosis, region of tissue resection and experimental group.

    • View popup
    Table 2.

    Intrinsic properties of putative L2/3 PN subtypes based on firing properties and AP shape

    Intrinsic propertyAccommodating (n = 7, 4)Regular Spiker (n = 44, 21)Notch (n = 18, 10)Stutter (n = 6, 4)Early Spiker (n = 7, 6)KW Test (p value, H)
    Resting membrane potential (mV)−68.47 ± 7.50−66.53 ± 7.46−68.33 ± 2.95−72.86 ± 5.25−65.77 ± 5.72p = 0.1943, H(4) = 6.07
    Input resistance (MΩ)137.60 ± 68.50136.8 ± 74.6488.42 ± 33.15136.10 ± 69.1495.73 ± 44.51p = 0.1202, H(4) = 7.31
    Voltage sag (%)5.69 ± 3.275.27 ± 2.595.22 ± 2.734.74 ± 2.794.10 ± 1.14p = 0.8742, H(4) = 1.22
    Membrane decay (ms)35.34 ± 6.9926.49 ± 7.4524.14 ± 5.9724.68 ± 6.9527.03 ± 5.94p = 0.0340, H(4) = 10.41
    AP threshold (mV)−37.57 ± 3.76−36.31 ± 5.47−36.84 ± 3.59−36.87 ± 10.16−41.50 ± 5.47p = 0.2593, H(4) = 5.28
    AP amplitude (mV)86.50 ± 7.9279.47 ± 8.5482.98 ± 6.3068.67 ± 10.0985.49 ± 6.76p = 0.0016, H(4) = 17.41
    AP half-width (ms)1.69 ± 0.431.30 ± 0.301.12 ± 0.221.22 ± 0.401.5 ± 0.34p = 0.0062, H(4) = 14.38
    AHP magnitude (mV)−15.90 ± 2.71−14.75 ± 3.67−15.27 ± 2.55−14.54 ± 3.14−16.48 ± 2.61p = 0.7774, H(4) = 1.77
    AHP latency (ms)11.56 ± 8.3614.96 ± 12.723.57 ± 1.125.05 ± 2.149.10 ± 5.45p < 0.0001, H(4) = 25.45
    ΔAHP (mV)−5.12 ± 3.95−3.72 ± 3.07−1.89 ± 1.53−5.53 ± 2.86−4.46 ± 2.68p = 0.0396, H(4) = 10.05
    AP broadening ratio1.30 ± 0 0.081.27 ± 0.111.24 ± 0.101.32 ± 0.071.22 ± 0.07p = 0.1265, H(4) = 7.18
    AP amplitude adaptation ratio0.91 ± 0.060.93 ± 0.060.96 ± 0.040.91 ± 0.050.91 ± 0.05p = 0.0794, H(4) = 8.355
    Initial instantaneous frequency (Hz)19.88 ± 3.6734.55 ± 14.2034.05 ± 21.4245.48 ± 13.2017.27 ± 4.10p = 0.0002, H(4) = 22.11
    Maximum firing rate (Hz)24.35 ± 4.2434.96 ± 11.7632.94 ± 13.3235.06 ± 8.3723.69 ± 5.75p = 0.0141, H(4) = 12.49
    Final instantaneous frequency (Hz)8.10 ± 2.3411.21 ± 3.379.59 ± 1.899.43 ± 7.678.48 ± 1.56p = 0.0152, H(4) = 12.31
    Accommodation ratio0.39 ± 0.100.37 ± 0.160.36 ± 0.120.20 ± 0.140.49 ± 0.11p = 0.0202, H(4) = 11.64
    • Intrinsic properties of accommodating, regular spiking, notch, stutter, and early spiking neurons.

    • View popup
    Table 3.

    Intrinsic properties of epileptic L2/3 PNs separated based on AHP shape and latency

    Intrinsic propertyfAHP neurons (n = 16, 12)fAHP + ADP neurons (n = 35, 18)mAHP neurons (n = 28, 13)Statistical comparisons (p value)
    Resting membrane potential (mV)−70.29 ± 5.23−68.09 ± 7.25−65.73 ± 6.49

    KW test

    p = 0.0577

    Input resistance (MΩ)135.10 ± 53.61104.40 ± 45.38137.90 ± 82.44

    KW test

    p = 0.2531

    Voltage sag (%)4.19 ± 2.975.11 ± 2.616.51 ± 2.63

    KW test

    p = 0.0194

    Membrane decay (ms)26.89 ± 6.0226.16 ± 7.2527.73 ± 7.29

    ANOVA

    p = 0.7114

    AP threshold (mV)−35.17 ± 6.58−37.46 ± 4.62−37.76 ± 5.68

    KW test

    p = 0.6493

    AP amplitude (mV)78.92 ± 10.7485.02 ± 7.4084.98 ± 8.19

    KW test

    p = 0.2345

    AP half-width (ms)1.26 ± 0.351.26 ± 0.361.40 ± 0.31

    KW test

    p = 0.1375

    AHP magnitude (mV)−16.42 ± 2.74−15.25 ± 3.56−15.14 ± 4.01

    KW test

    p = 0.6069

    AHP latency (ms)4.35 ± 1.314.11 ± 1.3620.84 ± 12.36

    KW test

    p < 0.0001

    ΔAHP (mV)−2.61 ± 3.06−2.49 ± 2.47−5.21 ± 2.91

    KW test

    p = 0.0003

    AP broadening ratio1.26 ± 0.091.26 ± 0 0.111.27 ± 0.10

    KW test

    p = 0.8880

    AP amplitude adaptation ratio0.93 ± 0.060.95 ± 0.030.90 ± 0.05

    KW test

    p = 0.0026

    Initial instantaneous frequency (Hz)32.49 ± 15.7233.53 ± 18.9332.30 ± 13.25

    KW test

    p = 0.9414

    Maximum firing rate (Hz)37.21 ± 13.9435.09 ± 13.1033.67 ± 12.03

    KW test

    p = 0.6588

    Final instantaneous frequency (Hz)11.43 ± 4.719.78 ± 2.01911.13 ± 4.36

    KW test

    p = 0.4298

    Accommodation ratio0.38 ± 0.150.38 ± 0.150.39 ± 0.13

    ANOVA

    p = 0.9230

    Max depolarization slope (dV/dT)207.80 ± 56.22228.80 ± 39.37206.70 ± 49.12

    ANOVA

    p = 0.1265

    Max repolarization slope (dV/dT)−50.44 ± 17.06−54.64 ± 10.75−44.74 ± 10.48

    ANOVA

    p = 0.0072

    • Intrinsic properties of fAHP, fAHP-ADP, and mAHP epileptic L2/3 PNs.

    • View popup
    Table 4.

    Intrinsic properties of L2/3 PNs split by control and epilepsy subtype

    Intrinsic propertyControl (n = 26, 5)MCD (n = 37, 13)Other epilepsies (n = 45, 15)Statistical comparison (p value)
    Resting membrane potential (mV)−69.98 ± 1.19−68.12 ± 7.13−67.76 ± 5.20

    ANOVA

    p = 0.3464

    Input resistance (MΩ)95.21 ± 36.54137.20 ± 63.21111.80 ± 67.72

    KW test

    p = 0.0068

    Voltage sag (%)8.42 ± 4.955.20 ± 2.345.26 ± 2.88

    KW test

    p = 0.0137

    Membrane decay (ms)26.23 ± 7.9526.7 ± 7.3726.77 ± 7.43

    KW test

    p = 0.9238

    AP threshold (mV)−45.26 ± 5.61−35.62 ± 6.09−38.16 ± 4.75

    KW test

    p < 0.0001

    AP amplitude (mV)84.07 ± 8.7375.60 ± 8.3784.64 ± 7.08

    KW test

    p < 0.0001

    AP half-width (ms)1.33 ± 0.261.21 ± 0.331.38 ± 0.33

    KW test

    p = 0.0064

    AHP magnitude (mV)−12.87 ± 3.19−15.29 ± 3.19−14.94 ± 3.36

    ANOVA

    p = 0.0102

    AHP latency (ms)10.58 ± 5.128.92 ± 6.328.65 ± 5.56

    KW test

    p = 0.0843

    ΔAHP (mV)−3.44 ± 3.10−3.86 ± 3.28−3.42 ± 2.73

    KW test

    p = 0.9027

    AP broadening ratio1.23 ± 0.091.28 ± 0.101.25 ± 0.10

    KW test

    p = 0.1324

    AP amplitude adaptation ratio0.95 ± 0.050.91 ± 0.060.94 ± 0.04

    Welch's

    p = 0.0421

    Maximum firing rate (Hz)32.80 ± 10.2926.68 ± 10.3324.34 ± 8.10

    ANOVA

    p = 0.0022

    Accommodation ratio0.46 ± 0.210.38 ± 0.160.48 ± 0.18

    Welch's

    p = 0.0359

    Maximum depolarization slope (dV/dT)250.20 ± 44.25211.80 ± 50.45218.50 ± 48.12

    ANOVA

    p = 0.0062

    Maximum repolarization slope (dV/dT)−53.85 ± 14.93−52.61 ± 12.97−48.26 ± 11.89

    KW test

    p = 0.0917

    • Intrinsic properties of L2/3 PNs from control, MCD and OE ex vivo brain tissue.

    • View popup
    Table 5.

    4-AP induces changes of epileptic L2/3 PN intrinsic properties

    Intrinsic propertyNo 4-AP (n = 17, 8)+4-AP (100 μM) (n = 17, 8)Statistical comparisons (p value)
    Input resistance (MΩ)146.00 ± 67.25111.40 ± 53.23

    Paired t test

    p = 0.0002

    Voltage sag (%)6.43 ± 3.586.68 ± 3.48

    Wilcoxon test

    p = 0.3060

    Membrane decay (ms)28.15 ± 7.9033.38 ± 17.54

    Wilcoxon test

    p = 0.3303

    AP threshold (mV)−38.14 ± 4.28−40.59 ± 4.93

    Paired t test

    p = 0.0433

    AP amplitude (mV)86.80 ± 7.6287.40 ± 4.62

    Paired t test

    p = 0.7729

    AP half-width (ms)1.28 ± 0.321.61 ± 0.39

    Paired test

    p = 0.0091

    AHP magnitude (mV)−16.85 ± 2.76−14.13 ± 3.26

    Wilcoxon test

    p = 0.0021

    AHP latency (ms)8.59 ± 3.7915.53 ± 5.19

    Paired t test

    p = 0.0002

    ΔAHP (mV)−5.45 ± 3.22−5.87 ± 4.50

    Paired t test

    p = 0.6689

    AP broadening ratio1.26 ± 0.101.34 ± 0.25

    Wilcoxon test

    p = 0.2078

    AP amplitude adaptation ratio0.91 ± 0.050.92 ± 0.07

    Paired t test

    p = 0.2812

    Maximum firing rate (Hz)26.08 ± 8.7025.29 ± 7.17

    Paired t test

    p = 0.3543

    Accommodation ratio (400 pA step)0.29 ± 0.100.44 ± 0.29

    Wilcoxon test

    p = 0.0273

    Accommodation ratio (500 pA step)0.27 ± 0.080.35 ± 0.16

    Wilcoxon test

    p = 0.0342

    Accommodation ratio (600 pA step)0.23 ± 0.090.34 ± 0.13

    Paired t test

    p = 0.0143

    Accommodation ratio (750 pA step)0.23 ± 0.070.35 ± 0.19

    Wilcoxon test

    p = 0.0105

    Accommodation ratio (800 pA step)0.22 ± 0.070.30 ± 0.14

    Wilcoxon test

    p = 0.0034

    Accommodation ratio (850 pA step)0.22 ± 0.090.45 ± 0.50

    Wilcoxon test

    p = 0.0068

    • Intrinsic properties of L2/3 epileptic PNs before and after 4-AP (100 µM) wash on.

Extended Data

  • Figures
  • Tables
  • Figure 2-1

    Other intrinsic properties of putative L2/3 PN subtypes. Other analyzed intrinsic properties were graphed to show spread and variability as follows: A) resting membrane potential (RMP, mV), B) input resistance (MΩ), C) voltage sag (%), D) membrane decay, E) AHP amplitude, F) Mean FR ± SEM vs injected current (pA), G) Max FR, H) final instantaneous frequency, and I) FR accommodation ratio ± SEM vs injected current (pA). Scatter plots include mean values ± SD. Download Figure 2-1, TIF file.

  • Figure 2-2

    PCA and K-means clustering of epileptic putative L2/3 PNs. A) Scree Plot used to determine the number of clusters for K-means clustering. B) Silhouette Value for each epileptic L2/3 PN based on cluster assignment. C) PCA 3D plot with neurons clustered based on 6 intrinsic properties with cluster centroids marked by an ‘X’. Download Figure 2-2, TIF file.

  • Table 2-1

    Post hoc test p-values for statistically significant properties based on putative L2/3 PN subtype. The correlated post-hoc test for comparing intrinsic properties from Table 2. Download Table 2-1, DOCX file.

  • Table 2-2

    Definitions of electrophysiologic parameters. How each intrinsic property was calculated based on the square 600ms current steps. Download Table 2-2, DOC file.

  • Figure 3-1

    Other intrinsic properties of L2/3 PN subtypes based on AHP shape. Other analyzed intrinsic properties were graphed to show spread and variability as follows: A) AP half-width, B) input resistance, C) initial instantaneous frequency, D) max instantaneous frequency, E) final instantaneous frequency, and F) FR accommodation ratio. Scatter plots include mean values ± SD. Download Figure 3-1, TIF file.

  • Table 3-1

    Group comparison values with post hoc adjusted p-values for statistically significant properties based on AHP subtype. The correlated post-hoc test for comparing intrinsic properties from Table 3. Download Table 3-1, DOCX file.

  • Table 4-1

    Group comparison values with post hoc adjusted p-values for statistically significant properties based on epilepsy subtype. The correlated post-hoc test for comparing intrinsic properties from Table 4. Download Table 4-1, DOCX file.

Back to top

In this issue

eneuro: 12 (5)
eNeuro
Vol. 12, Issue 5
May 2025
  • Table of Contents
  • Index by author
  • Masthead (PDF)
Email

Thank you for sharing this eNeuro article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterizing the Diversity of Layer 2/3 Human Neocortical Neurons in Pediatric Epilepsy
(Your Name) has forwarded a page to you from eNeuro
(Your Name) thought you would be interested in this article in eNeuro.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
Characterizing the Diversity of Layer 2/3 Human Neocortical Neurons in Pediatric Epilepsy
J. Keenan Kushner, Paige B. Hoffman, Christine R. Brzezinski, Matthew N. Svalina, Brent R. O’Neill, Todd C. Hankinson, Charles C. Wilkinson, Michael H. Handler, Serapio M. Baca, Molly M. Huntsman, Allyson L. Alexander
eNeuro 17 April 2025, 12 (5) ENEURO.0247-24.2025; DOI: 10.1523/ENEURO.0247-24.2025

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Characterizing the Diversity of Layer 2/3 Human Neocortical Neurons in Pediatric Epilepsy
J. Keenan Kushner, Paige B. Hoffman, Christine R. Brzezinski, Matthew N. Svalina, Brent R. O’Neill, Todd C. Hankinson, Charles C. Wilkinson, Michael H. Handler, Serapio M. Baca, Molly M. Huntsman, Allyson L. Alexander
eNeuro 17 April 2025, 12 (5) ENEURO.0247-24.2025; DOI: 10.1523/ENEURO.0247-24.2025
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Significance Statement
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
    • Synthesis
    • Author Response
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Keywords

  • DNET
  • focal cortical dysplasia
  • gliosis
  • layer 2/3 pyramidal neurons
  • intrinsic properties
  • tuberous sclerosis

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

Research Article: New Research

  • Deletion of endocannabinoid synthesizing enzyme DAGLα in Pcp2-positive cerebellar Purkinje cells decreases depolarization-induced short-term synaptic plasticity, reduces social preference, and heightens anxiety
  • Release of extracellular matrix components after human traumatic brain injury
  • Action intentions reactivate representations of task-relevant cognitive cues
Show more Research Article: New Research

Disorders of the Nervous System

  • Release of extracellular matrix components after human traumatic brain injury
  • Gene variants related to primary familial brain calcification: perspectives from bibliometrics and meta-analysis
  • Expression of HDAC3-Y298H Point Mutant in Medial Habenula Cholinergic Neurons Has No Effect on Cocaine-Induced Behaviors
Show more Disorders of the Nervous System

Subjects

  • Disorders of the Nervous System
  • Home
  • Alerts
  • Follow SFN on BlueSky
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Latest Articles
  • Issue Archive
  • Blog
  • Browse by Topic

Information

  • For Authors
  • For the Media

About

  • About the Journal
  • Editorial Board
  • Privacy Notice
  • Contact
  • Feedback
(eNeuro logo)
(SfN logo)

Copyright © 2025 by the Society for Neuroscience.
eNeuro eISSN: 2373-2822

The ideas and opinions expressed in eNeuro do not necessarily reflect those of SfN or the eNeuro Editorial Board. Publication of an advertisement or other product mention in eNeuro should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in eNeuro.